Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer’s disease in adults with Down syndrome

被引：0

作者：

Alberto Lleó

Henrik Zetterberg

Jordi Pegueroles

Thomas K. Karikari

María Carmona-Iragui

Nicholas J. Ashton

Victor Montal

Isabel Barroeta

Juan Lantero-Rodríguez

Laura Videla

Miren Altuna

Bessy Benejam

Susana Fernandez

Silvia Valldeneu

Diana Garzón

Alexandre Bejanin

Maria Florencia Iulita

Valle Camacho

Santiago Medrano-Martorell

Olivia Belbin

Jordi Clarimon

Sylvain Lehmann

Daniel Alcolea

Rafael Blesa

Kaj Blennow

Juan Fortea

机构：

[1] Hospital de la Santa Creu i Sant Pau,Memory Unit, Department of Neurology

[2] Biomedical Research Institute Sant Pau,Department of Psychiatry and Neurochemistry

[3] Universitat Autònoma de Barcelona,Clinical Neurochemistry Laboratory

[4] Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED),Department of Neurodegenerative Disease

[5] Institute of Neuroscience and Physiology,Wallenberg Centre for Molecular and Translational Medicine

[6] the Sahlgrenska Academy at the University of Gothenburg,Department of Old Age Psychiatry

[7] Sahlgrenska University Hospital,undefined

[8] UK Dementia Research Institute at UCL,undefined

[9] UCL Institute of Neurology,undefined

[10] Barcelona Down Medical Center,undefined

[11] Fundació Catalana Síndrome de Down,undefined

[12] University of Gothenburg,undefined

[13] Institute of Psychiatry,undefined

[14] Psychology and Neuroscience,undefined

[15] King’s College London,undefined

[16] NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation,undefined

[17] Hospital del Mar-Universitat Autònoma Barcelona (UAB),undefined

[18] The Institute for Neurosciences of Montpellier,undefined

[19] Université de Montpellier,undefined

[20] Centre Hospitalier Universitaire de Montpellier,undefined

[21] INSERM,undefined

来源：

Nature Communications | / 12卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Plasma tau phosphorylated at threonine 181 (p-tau181) predicts Alzheimer’s disease (AD) pathology with high accuracy in the general population. In this study, we investigated plasma p-tau181 as a biomarker of AD in individuals with Down syndrome (DS). We included 366 adults with DS (240 asymptomatic, 43 prodromal AD, 83 AD dementia) and 44 euploid cognitively normal controls. We measured plasma p-tau181 with a Single molecule array (Simoa) assay. We examined the diagnostic performance of p-tau181 for the detection of AD and the relationship with other fluid and imaging biomarkers. Plasma p-tau181 concentration showed an area under the curve of 0.80 [95% CI 0.73–0.87] and 0.92 [95% CI 0.89–0.95] for the discrimination between asymptomatic individuals versus those in the prodromal and dementia groups, respectively. Plasma p-tau181 correlated with atrophy and hypometabolism in temporoparietal regions. Our findings indicate that plasma p-tau181 concentration can be useful to detect AD in DS.

引用

共 35 条

[1]

Ballard C(2016)Dementia in Down’s syndrome Lancet Neurol. 15 622-636

[2]

Mobley W(2007)The four ages of Down syndrome Eur. J. Public Health 17 221-225

[3]

Hardy J(2017)A prospective 20-year longitudinal follow-up of dementia in persons with Down syndrome J. Intellect. Disabil. Res. 61 843-852

[4]

Williams G(2020)Clinical and biomarker changes of Alzheimer’s disease in adults with Down syndrome: a cross-sectional study Lancet 395 1988-1997

[5]

Corbett A(2019)Association of dementia with mortality among adults with Down syndrome older than 35 years JAMA Neurol. 76 152-160

[6]

Bittles AH(2019)Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease Alzheimers Res. Ther. 11 26-869

[7]

Bower C(2018)Plasma and CSF biomarkers for the diagnosis of Alzheimer’s disease in adults with Down syndrome: a cross-sectional study Lancet Neurol. 17 860-589

[8]

Hussain R(2020)Cerebrospinal fluid biomarkers of Alzheimer’s disease in a cohort of adults with Down syndrome Alzheimers Dement. (Amst.) 12 e12057-849

[9]

Glasson EJ(2019)Blood-based molecular biomarkers for Alzheimer’s disease Mol. Brain 12 577-254

[10]

McCarron M(2018)Neurofilaments as biomarkers in neurological disorders Nat. Rev. Neurol. 14 841-e1659

← 1 2 3 4 →